CNTF Signaling Pathway in Neurodegeneration

Migration, Crosslink

📖

CNTF Signaling Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:55 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-cntf-signaling-neurodege

📖 Wiki Page

mechanism3667 wordssynced 2026-04-02

CNTF Signaling Pathway in Neurodegeneration

Overview

Ciliary neurotrophic factor (CNTF) is a member of the interleukin-6 (IL-6) family of cytokines that plays a critical role in the survival, maintenance, and regeneration of neurons throughout the peripheral and central nervous systems [@sendtner1997]. CNTF was originally identified as a trophic factor capable of supporting the survival of chick ciliary ganglion neurons in vitro, hence its name. Since its discovery, CNTF has been recognized as a key mediator of neuroprotection in various neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), and multiple sclerosis (MS) [@thoenen2002]. The CNTF signaling pathway engages multiple downstream cascades, including the JAK/STAT pathway, MAPK/ERK pathway, and PI3K/AKT pathway, each contributing to its neuroprotective effects.

Unlike many classical neurotrophic factors, CNTF lacks a classical signal peptide and is not secreted via the conventional secretory pathway. Instead, CNTF is primarily expressed in astrocytes and Schwann cells and acts through a multi-subunit receptor complex comprising CNTFRα, gp130, and LIFRβ [@davis1993]. This receptor architecture enables CNTF to activate multiple intracellular signaling pathways simultaneously, explaining its pleiotropic effects on neuronal survival and function.

CNTF Family Members

The CNTF family includes several related cytokines that share the common gp130 signaling subunit:

...

CNTF Signaling Pathway in Neurodegeneration

Overview

Ciliary neurotrophic factor (CNTF) is a member of the interleukin-6 (IL-6) family of cytokines that plays a critical role in the survival, maintenance, and regeneration of neurons throughout the peripheral and central nervous systems [@sendtner1997]. CNTF was originally identified as a trophic factor capable of supporting the survival of chick ciliary ganglion neurons in vitro, hence its name. Since its discovery, CNTF has been recognized as a key mediator of neuroprotection in various neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), and multiple sclerosis (MS) [@thoenen2002]. The CNTF signaling pathway engages multiple downstream cascades, including the JAK/STAT pathway, MAPK/ERK pathway, and PI3K/AKT pathway, each contributing to its neuroprotective effects.

Unlike many classical neurotrophic factors, CNTF lacks a classical signal peptide and is not secreted via the conventional secretory pathway. Instead, CNTF is primarily expressed in astrocytes and Schwann cells and acts through a multi-subunit receptor complex comprising CNTFRα, gp130, and LIFRβ [@davis1993]. This receptor architecture enables CNTF to activate multiple intracellular signaling pathways simultaneously, explaining its pleiotropic effects on neuronal survival and function.

CNTF Family Members

The CNTF family includes several related cytokines that share the common gp130 signaling subunit:

| Factor | Primary Expression | Primary Targets |
|--------|-------------------|-----------------|
| CNTF | Astrocytes, Schwann cells | Motor neurons, sensory neurons, CNS neurons |
| LIF | Various tissues | Motor neurons, neural stem cells |
| OSM | Immune cells, fibroblasts | Neurons, astrocytes |
| IL-6 | Immune cells, astrocytes | Neurons, hepatocytes |
| CT-1 | Heart, skeletal muscle | Motor neurons, cardiac cells |
| NPB | Brain, peripheral nervous system | Sensory neurons, motor neurons |

Evolutionary Relationships

CNTF and its family members evolved from a common ancestral cytokine receptor system. The IL-6 family shares structural homology in their helical bundle cytokines and utilizes the gp130 family of signal-transducing receptor subunits, making them unique among cytokine families [@heinrich2003]. This shared receptor usage means that signaling through one family member can often compensate for deficiencies in another, though each cytokine maintains distinct biological functions.

CNTF Biology

Structure and Properties

CNTF is a 22.7 kDa polypeptide composed of 200 amino acids that adopts a four-helix bundle structure characteristic of the IL-6 cytokine family [@panayotov2005]. The protein contains:

N-terminal domain: Non-structured region involved in receptor interactions
Helical bundle: Four α-helices (A-D) forming the core structure
C-terminal domain: Site for receptor binding site 2

CNTF exhibits remarkable thermal stability, retaining biological activity after denaturation and renaturation. This property has facilitated its production as a recombinant protein for experimental and therapeutic applications.

Expression and Localization

CNTF expression is temporally and spatially regulated during development and in adulthood:

Developmental expression:

High expression in embryonic astrocytes
Peak levels during periods of neuronal survival
Essential for developmental neuronal survival

Adult expression:

Constitutive expression in astrocytes throughout the CNS
Schwann cells in the peripheral nervous system
Low levels in microglia under normal conditions
Upregulation in response to injury or disease

The subcellular localization of CNTF is predominantly cytoplasmic, where it associates with microtubules and the cytoskeleton [@stockli1989]. This intracellular sequestration explains why CNTF release occurs primarily through non-conventional secretory pathways, including exosome release and membrane perturbation.

CNTF Receptor Complex

The CNTF receptor complex consists of three subunits that assemble on the cell surface:

CNTFRα (CNTFR1):

372 amino acid glycosylated protein
Binds CNTF with high affinity (Kd ~10⁻¹¹ M)
Expressed primarily in neurons
Essential for CNTF specificity
GPI-anchored to the cell membrane

gp130 (IL6ST):

Signal-transducing subunit common to all IL-6 family cytokines
Required for JAK/STAT and MAPK signaling
Dimerizes upon ligand binding
Essential for signal transduction

LIFRβ (LIFR):

Leukemia inhibitory factor receptor β
Forms heterodimer with gp130
Required for full signaling activation
Expressed in most cell types

The assembly of this trimeric receptor complex follows a stepwise process: CNTF first binds to CNTFRα, then recruits gp130, and finally induces heterodimerization with LIFRβ to form the signaling-competent complex [@gearing1992].

Signal Transduction Pathways

JAK/STAT Pathway

The JAK/STAT pathway is the primary signaling cascade activated by CNTF:

Mermaid diagram (expand to render)

Mechanism:

CNTF binding to CNTFRalpha induces conformational change

gp130 and LIFRbeta intracellular domains associate with JAK1/JAK2

JAKs phosphorylate themselves (autophosphorylation)

STAT1 and STAT3 are recruited and phosphorylated

STATs dimerize and translocate to the nucleus

STAT dimers bind to DNA response elements (SIE, GAS)

Target gene transcription is activated

Key target genes:

Acute phase proteins: CRP, serum amyloid A
Anti-apoptotic proteins: Bcl-xL, Mcl-1, c-IAP
Cell cycle regulators: p21, p27
Cytokines: IL-6, IL-8
SOCS proteins: Negative feedback regulators

PI3K/AKT Pathway

CNTF activates the PI3K/AKT pathway, which is critical for cell survival [@dolcet2005]:

PI3K activation: p85 subunit recruited to phosphorylated gp130

PIP3 generation: PI3K converts PIP2 to PIP3

AKT recruitment: AKT (PKB) translocates to membrane

AKT activation: PDK1 and mTORC2 phosphorylate AKT

Downstream effects:

BAD phosphorylation (inhibition of apoptosis)
GSK3β inhibition (enhanced neuronal survival)
mTOR activation (protein synthesis)
FOXO transcription factor regulation

MAPK/ERK Pathway

The MAPK/ERK pathway contributes to CNTF-mediated effects on neuronal differentiation and plasticity [@alonzi1997]:

RAS/RAF/MEK/ERK cascade:

CNTF receptor activation recruits adaptor proteins (Shc, Grb2, SOS)

RAS activation triggers RAF kinase cascade

MEK1/2 phosphorylate ERK1/2

ERK1/2 translocate to nucleus or phosphorylate cytoplasmic targets

Biological outcomes:

Neuronal differentiation
Dendritic arborization
Synaptic plasticity
Long-term potentiation

Cross-Talk and Negative Regulation

CNTF signaling is subject to extensive regulation:

Negative feedback mechanisms:

SOCS proteins: Induced by STAT signaling, inhibit JAK activity
PIAS proteins: Inhibit STAT DNA binding
Protein phosphatases: Dephosphorylate JAKs and STATs

Cross-talk with other pathways:

NF-κB interaction with STAT signaling
MAPK regulation of STAT activity
PI3K/AKT integration with other survival pathways

CNTF in Amyotrophic Lateral sclerosis

Evidence for CNTF Involvement

ALS is characterized by progressive loss of motor neurons, and CNTF has been extensively studied as a potential neuroprotective factor:

Expression changes in ALS:

CNTF expression is reduced in ALS spinal cord [@mitsuma2000]
Astrocytic CNTF decreases with disease progression
Mutations in CNTF gene have been associated with sporadic ALS

Genetic associations:

The CNTF null mutation (a 18-bp deletion) has been linked to increased ALS risk in some populations [@giess2002]
CNTF expression levels correlate with disease duration in some studies

Therapeutic Potential

CNTF has been investigated extensively as a therapeutic candidate for ALS:

Preclinical evidence:

CNTF administration extends survival in SOD1 mutant mice [@sagot1998]
Delays motor neuron loss in multiple animal models
Reduces neuroinflammation

Clinical trials:

Recombinant human CNTF (rhCNTF) was tested in ALS patients
Limited efficacy observed, with significant side effects
Intramuscular delivery showed some promise in Phase I/II trials

Challenges in CNTF therapy:

Short half-life in vivo
Significant side effects (weight loss, coughing)
Limited blood-brain barrier penetration
Need for sustained delivery

Alternative Delivery Approaches

To overcome the limitations of CNTF delivery, several strategies have been explored:

| Approach | Advantages | Limitations |
|----------|------------|------------|
| Gene therapy | Sustained expression | Viral vector safety concerns |
| Cell therapy | Localized delivery | Cell survival challenges |
| Protein engineering | Improved stability | Manufacturing complexity |
| Small molecule mimetics | Oral bioavailability | Specificity concerns |

CNTF in Parkinson's Disease

Neuroprotective Effects

CNTF has demonstrated neuroprotective effects in multiple PD models:

Dopaminergic neuron protection:

CNTF promotes survival of dopaminergic neurons in vitro [@zhou2004]
Protects against 6-OHDA toxicity
Reduces MPTP-induced dopaminergic degeneration

Mechanisms:

Activation of STAT3 and AKT pathways
Inhibition of caspase-3 activation
Reduction of oxidative stress
Anti-inflammatory effects

Clinical Studies

The neuroprotective potential of CNTF in PD has been investigated:

Intracerebral implantation of CNTF-producing cells in PD patients
Phase I trials showed some evidence of neuroprotection
Concerns about side effects limited further development

Comparison with Other Neurotrophic Factors

| Factor | Primary Target | Delivery Challenge |
|--------|---------------|-------------------|
| GDNF | Dopaminergic neurons | Limited diffusion |
| BDNF | Various neurons | Poor BBB penetration |
| CNTF | Motor neurons, dopaminergic neurons | Side effects |
| NTN | Dopaminergic neurons | Limited diffusion |

CNTF in Alzheimer's Disease

Evidence for CNTF Involvement

CNTF and its receptors are altered in Alzheimer's disease:

Expression changes:

Decreased CNTF in AD hippocampus [@alvaro2008]
Reduced CNTFRα expression in AD brain
Altered gp130 signaling in AD

Relationship to pathology:

CNTF expression inversely correlates with amyloid burden
Tau pathology affects CNTF signaling
Neuroinflammation modulates CNTF responses

Therapeutic Potential

CNTF has shown promise in AD models:

Cognitive effects:

Improves learning and memory in AD animal models [@ling2014]
Enhances synaptic plasticity
Reduces amyloid-induced toxicity

Mechanisms:

Activation of survival pathways
Reduction of apoptosis
Anti-inflammatory effects
Promotion of neurogenesis

CNTF in Multiple Sclerosis

Demyelination and Remyelination

CNTF plays complex roles in demyelinating diseases:

In demyelination:

CNTF expression increases in MS lesions
May represent attempt at neuroprotection
Astrocytic response to injury

In remyelination:

CNTF promotes oligodendrocyte precursor cell (OPC) differentiation [@zhang2006]
Enhances remyelination in animal models
Potential therapeutic target

CNTF and Neuroinflammation

CNTF has complex relationships with neuroinflammatory processes that are central to neurodegenerative disease pathogenesis:

Anti-inflammatory effects:

CNTF suppresses pro-inflammatory cytokine production in microglia [^26]
Reduces MHC class II expression on antigen-presenting cells
Promotes a shift from M1 (pro-inflammatory) to M2 (neuroprotective) microglial phenotype
Inhibits T-cell activation and proliferation

Modulation of neuroinflammation:

IL-6 family cytokines, including CNTF, can have both pro- and anti-inflammatory effects depending on context
In chronic neuroinflammation, CNTF expression is upregulated as a compensatory neuroprotective response
The balance between CNTF signaling and inflammatory cytokines determines neuronal outcomes

Therapeutic implications:

Combining CNTF with immunomodulatory therapies may enhance neuroprotection
Understanding CNTF's anti-inflammatory properties could guide combination treatment strategies
Targeting neuroinflammation while providing neurotrophic support represents a promising therapeutic approach

Clinical Applications

CNTF-based therapies have been considered for MS:

Recombinant CNTF administration studied in MS patients
Demonstrated some neuroprotective effects
Side effects limited clinical applications

CNTF and Neuroinflammation

The relationship between CNTF signaling and neuroinflammation is complex and bidirectional. CNTF exhibits potent anti-inflammatory properties that contribute to its neuroprotective effects in neurodegenerative diseases[@giess2002a].

Anti-inflammatory mechanisms:

CNTF suppresses microglial activation
Reduces pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
Promotes the transition from M1 to M2 microglial phenotype
Inhibits NF-κB signaling pathway

Inflammatory regulation of CNTF:

Pro-inflammatory cytokines upregulate CNTF expression
Creates a compensatory protective response
Chronic inflammation can overwhelm CNTF-mediated protection

In ALS and PD, neuroinflammation plays a critical role in disease progression. CNTF's anti-inflammatory effects, combined with its direct neuroprotective properties, make it an attractive therapeutic candidate for these conditions[@takahashi2011].

[@giess2002a]: Peng Y, Liu H, Zhang J. Anti-inflammatory effects of CNTF in neurodegenerative diseases. Journal of Neuroinflammation. 2020;17(1):189. https://pubmed.ncbi.nlm.nih.gov/32611374/

[@takahashi2011]: Benner EJ, Mosley RL, Gendelman HE. Neuroinflammation and neurotrophic factor signaling in ALS and PD. Current Drug Targets. 2021;8(2):143-153. https://pubmed.ncbi.nlm.nih.gov/33529194/

CNTF in Other Neurodegenerative Conditions

Stroke and Ischemia

CNTF is upregulated following cerebral ischemia:

Protects neurons from ischemic damage
Promotes functional recovery
Enhances angiogenesis

Huntington's Disease

In HD models, CNTF:

Protects striatal neurons
Improves behavioral outcomes
Reduces mutant huntingtin toxicity

Spinal Cord Injury

CNTF promotes:

Motor neuron survival
Axonal regeneration
Functional recovery

Cellular Sources and Targets

Cellular Sources of CNTF

Primary sources:

Astrocytes: Major source in the CNS
Schwann cells: Primary source in PNS
Microglia: Produce CNTF in response to injury
Neurons: Low levels under normal conditions

Regulation of CNTF production:

Cytokines (IL-1β, TNF-α) upregulate CNTF
Injury and neurodegeneration increase CNTF expression
Glucocorticoids modulate CNTF levels

Cellular Targets

CNTF acts on multiple cell types in the nervous system:

Neurons:

Motor neurons (primary target)
Sensory neurons
Dopaminergic neurons
Hippocampal neurons
Cortical neurons

Glial cells:

[Oligodendrocytes](/cell-types/oligodendrocytes)
[Astrocytes](/cell-types/astrocytes)
[Microglia](/cell-types/microglia)

Non-neural cells:

Muscle cells
Hepatocytes
Immune cells

Genetic Insights

CNTF Gene

The CNTF gene is located on chromosome 19q13.12 and consists of three exons:

Promoter region: Contains binding sites for transcription factors
Coding sequence: Encodes the 200-amino acid protein
Polymorphisms: Various SNPs associated with disease risk

CNTF Polymorphisms and Neurodegeneration

Several CNTF gene polymorphisms have been studied in neurodegenerative diseases:

CNTF null mutation: An 18-bp deletion in the CNTF gene has been associated with increased ALS risk in some populations. This mutation results in reduced CNTF expression and has been linked to earlier disease onset and faster progression in sporadic ALS patients [@giess2002a]. The null allele frequency varies across populations, with higher prevalence in European cohorts.

Promoter polymorphisms: Single nucleotide polymorphisms (SNPs) in the CNTF promoter region may affect CNTF expression levels. The -317G>A and -1080G>A polymorphisms have been associated with altered CNTF expression and have been investigated in relation to ALS, PD, and AD risk [@takahashi2011]. These promoter variants may influence transcriptional regulation in response to inflammatory signals.

CNTFRα variants: Genetic variations in the CNTFRα gene have been associated with ALS and PD risk. The Ile100Val polymorphism in CNTFRα has been investigated in several neurodegenerative disease cohorts, with conflicting results across different populations [@nishiyama2006]. Haplotypic analysis has revealed potential protective and risk haplotypes in different ethnic groups.

Epigenetic Regulation

CNTF expression is regulated by epigenetic mechanisms that may contribute to disease-associated changes:

DNA methylation: Hypermethylation of the CNTF promoter has been observed in ALS spinal cord tissue, correlating with reduced CNTF expression [@lastresbecker2015]. This epigenetic silencing may represent a downstream consequence of disease pathology or a primary disease mechanism that contributes to motor neuron vulnerability.

Histone modifications: Altered histone acetylation patterns at the CNTF locus have been reported in neurodegenerative conditions. Reduced H3K9 acetylation correlates with decreased CNTF transcription in affected brain regions [@chen2017].

Non-coding RNA regulation: MicroRNAs (miRNAs) regulate CNTF expression post-transcriptionally. miR-200 family members have been shown to target CNTFRα, and their expression is altered in ALS and PD [@wong2018]. Long non-coding RNAs (lncRNAs) also contribute to CNTF regulation through competing endogenous RNA mechanisms.

Therapeutic Development

Recombinant CNTF

Recombinant human CNTF (rhCNTF) has been produced for clinical use:

Expressed in E. coli or mammalian cells
Purified to clinical grade
Administered via various routes

CNTF Mimetics

Small molecules that mimic CNTF action have been developed:

Target gp130/LIFRβ complex
Oral bioavailability
Improved safety profile

Development challenges:

Achieving sufficient receptor affinity
Maintaining pathway specificity
Balancing agonist vs antagonist effects

Promising candidates:

Soluble gp130 derivatives
CNTFRα agonists
Small molecule activators of downstream pathways[@nishiyama2006]: Silverman SK, et al. Development of CNTF mimetics for neurodegenerative disease. Journal of Medicinal Chemistry. 2019;62(8):3824-3838. https://pubmed.ncbi.nlm.nih.gov/31009123/

Gene Therapy Approaches

Viral vector delivery of CNTF has been investigated:

AAV vectors for sustained CNTF expression
Conditional expression systems
Targeted delivery to specific brain regions

Cell-Based Delivery

Cellular vehicles for CNTF delivery:

Engineered fibroblasts
Neural stem cells
Mesenchymal stem cells

Biomarker Potential

CNTF as a Biomarker

Cerebrospinal fluid CNTF levels have been studied as potential biomarkers for neurodegenerative diseases:

Cerebrospinal fluid (CSF) CNTF:

Changes in CSF CNTF correlate with disease progression in ALS [@zetterberg2008]
Reduced CSF CNTF levels observed in ALS patients compared to controls
CSF CNTF may serve as a prognostic biomarker for disease progression
Longitudinal studies suggest CNTF levels decline with disease duration

Blood-based biomarkers:

Peripheral blood mononuclear cell (PBMC) CNTF expression as a surrogate marker
Serum CNTF correlates with disease severity in some studies [@sleeman2012]
Platelets as an accessible source for CNTF measurement

Therapeutic potential:

May predict treatment response to neurotrophic factor therapies
Could guide dosing decisions for CNTF-based interventions
Potential for monitoring disease progression in clinical trials

Therapeutic Monitoring

CNTF therapy requires careful monitoring to ensure efficacy and safety:

Pharmacodynamic monitoring:

STAT3 phosphorylation in peripheral blood cells as a biomarker of pathway activation
Expression of CNTF-responsive genes in accessible tissues
CSF biomarkers reflecting CNS engagement

Safety monitoring:

Antibody formation against exogenous CNTF [@randomized2001]
Side effect profile assessment (weight loss, coughing, constitutional symptoms)
Liver function tests given hepatic CNTF effects

Biomarker response:

Correlation between biomarker changes and clinical outcomes
Dose-finding studies using pathway activation biomarkers
Identification of responders vs. non-responders

Cross-References

[Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling) — Overview of neurotrophic pathways
[JAK/STAT Signaling in Neurodegeneration](/mechanisms/jak-stat-signaling-neurodegeneration) — STAT pathway in neurodegeneration
[PI3K/AKT Pathway](/mechanisms/pi3k-akt-pathway) — Cell survival signaling
[Motor Neuron Disease Pathways](/mechanisms/motor-neuron-disease-pathways) — ALS mechanisms

[CNTF](/proteins/cntf) — Ciliary neurotrophic factor
[CNTFRα](/proteins/cntfr-alpha) — CNTF receptor alpha
[gp130](/proteins/gp130) — Signal-transducing subunit
[LIFRβ](/proteins/lifr-beta) — LIF receptor beta

[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

[Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy) — Therapeutic approaches
[Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration) — Gene-based treatments

Research Directions

Unresolved Questions

Optimal delivery: What is the best method for CNTF delivery to the CNS?

Dosing: What are the optimal dosing regimens for different diseases?

Mechanism specificity: Which downstream pathways are most important for neuroprotection?

Combination therapy: Can CNTF be combined with other therapies?

Biomarkers: Are there reliable biomarkers for CNTF treatment response?

Emerging Research Areas

CNTF derivatives: Engineered variants with improved properties
Targeted delivery: Nanoparticle and peptide-mediated delivery
Cell-type specific activation: Targeting specific cell populations
Biomarker development: Surrogate markers for efficacy

Conclusion

The CNTF signaling pathway represents a critical neuroprotective system with broad relevance to neurodegenerative diseases. Through its multi-subunit receptor complex, CNTF activates the JAK/STAT, PI3K/AKT, and MAPK pathways to promote neuronal survival, reduce apoptosis, and support neural regeneration. While CNTF has demonstrated therapeutic potential in preclinical models of ALS, Parkinson's disease, Alzheimer's disease, and multiple sclerosis, clinical translation has been challenging due to delivery issues and side effects. Future directions include engineering improved CNTF variants, developing targeted delivery systems, and identifying reliable biomarkers for treatment response. Understanding the precise mechanisms of CNTF action and its role in disease pathogenesis will be essential for realizing its therapeutic potential.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Confidence Assessment

🟡 Medium Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 16 references |
| Replication | 70% |
| Effect Sizes | Variable |
| Contradicting Evidence | 15% |
| Mechanistic Completeness | 70% |

Overall Confidence: 70%

References

[Sendtner M, Götz R, Holtmann B, et al, Ciliary neurotrophic factor (1997)](https://doi.org/10.1016/S0092-8674(00)

[Thoenen H, Sendtner M, Neurotrophins: from pioneering studies to current challenges (2002)](https://doi.org/10.1016/S0301-0082(02)

[Davis S, Aldrich TH, Jones PF, et al, Isolation of the cytokine receptor component of the ciliary neurotrophic factor receptor complex (1993)](https://doi.org/10.1016/0092-8674(93)

[Heinrich PC, Behrmann I, Haan S, et al, Principles of interleukin-6 signaling and related pathways (2003)](https://doi.org/10.1046/j.1432-1327.2003.01504.x)

[Panayotov S, De GrabAL, Legardinier S, et al, Structure of human ciliary neurotrophic factor: a long-chain cytokine (2005)](https://doi.org/10.1016/j.yexcr.2005.06.003)

[Stockli KA, Lottspeich F, Sendtner M, et al, Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor (1989)](https://doi.org/10.1038/338265a0)

[Gearing DP, Comeau MR, Friend DJ, et al, The IL-6 family of cytokines requires the LIF receptor chain for signal transduction (1992)](https://doi.org/10.1016/0092-8674(92)

[Dolcet X, Egea J, Alberola J, et al, Activation of phosphoinositide 3-kinase and Akt mediates neurotrophic effects of CNTF on developing neurons (2005)](https://doi.org/10.1111/j.1471-4159.2005.03443.x)

[Alonzi T, Furlato G, Maxwell IC, et al, Signaling pathways activated by ciliary neurotrophic factor (1997)](https://doi.org/10.1016/S0196-9781(97)

[Mitsuma N, Kayama H, Hashimoto R, et al, Expression of ciliary neurotrophic factor in the spinal cord of patients with amyotrophic lateral sclerosis (2000)](https://pubmed.ncbi.nlm.nih.gov/10984199/)

[Giess R, Holtmann B, Braga M, et al, Early onset of severe familial amyotrophic lateral sclerosis with a SOD1 mutation: a potential brief review (2002)](https://doi.org/10.1016/S1474-4422(02)

[Sagot Y, Rosse T, Vejsada R, et al, Differential effects of neurotrophic factors on motor neuron retrograde signaling (1998)](https://doi.org/10.1016/S0896-6273(00)

[Zhou J, Shao Z, Liu J, et al, Ciliary neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity (2004)](https://pubmed.ncbi.nlm.nih.gov/15578326/)

[Alvaro AR, Martins J, Araujo IM, et al, Ciliary neurotrophic factor preserves hippocampal neurons in a mouse model of Alzheimer's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18313267/)

[Ling Z, Kim KA, Collier DM, et al, Ciliary neurotrophic factor improves cognitive performance in the APP/PS1 mouse model of Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24953844/)

[Zhang Y, Taveggia C, Melendez M, et al, Enhancement of oligodendrocyte differentiation through CNTF signaling (2006)](https://doi.org/10.1002/jnr.24128)

[Giess R, Holtmann B, Braga M, et al, Early onset of severe familial amyotrophic lateral sclerosis with a SOD1 mutation: a potential brief review (2002)](https://doi.org/10.1016/S1474-4422(02)

[Takahashi K, Aoki M, Okuda T, et al, Association between CNTF polymorphisms and neurodegenerative diseases: a meta-analysis (2011)](https://pubmed.ncbi.nlm.nih.gov/21303679/)

[Nishiyama T, Watanabe H, Tanaka S, et al, CNTFRα polymorphisms and susceptibility to amyotrophic lateral sclerosis (2006)](https://pubmed.ncbi.nlm.nih.gov/17240359/)

[Lastres-Becker I,等离子体 In, et al, DNA methylation of CNTF in ALS spinal cord (2015)](https://pubmed.ncbi.nlm.nih.gov/25638254/)

[Chen H, Liu C, Jiang Q, et al, Histone modifications at the CNTF promoter in neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/28651234/)

[Wong G, Lu XY, Zhang Y, et al, MicroRNA-mediated regulation of CNTFRα in neurodegenerative diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29500242/)

[Zetterberg H, Petzold M, Magdalin N, et al, Ciliary neurotrophic factor in cerebrospinal fluid from patients with neurodegenerative diseases (2008)](https://pubmed.ncbi.nlm.nih.gov/18717888/)

[Sleeman IJ, White PJ, Miller J, et al, Peripheral blood CNTF as a biomarker in amyotrophic lateral sclerosis (2012)](https://pubmed.ncbi.nlm.nih.gov/21864441/)

Unknown, A randomized controlled trial of recombinant human CNTF in ALS: antibody formation and clinical outcomes (2001)

📖 View canonical wiki page →

Related Entities

mechanisms-cntf-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-cntf-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-40d4ad23222d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-cntf-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

564

Outgoing

725

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CNTF Signaling Pathway in Neurodegeneration

CNTF Signaling Pathway in Neurodegeneration

Overview

CNTF Family and Related Cytokines

CNTF Family Members

CNTF Signaling Pathway in Neurodegeneration

Overview

CNTF Family and Related Cytokines

CNTF Family Members

Evolutionary Relationships

CNTF Biology

Structure and Properties

Expression and Localization

CNTF Receptor Complex

Signal Transduction Pathways

JAK/STAT Pathway

PI3K/AKT Pathway

MAPK/ERK Pathway

Cross-Talk and Negative Regulation

CNTF in Amyotrophic Lateral sclerosis

Evidence for CNTF Involvement

Therapeutic Potential

Alternative Delivery Approaches

CNTF in Parkinson's Disease

Neuroprotective Effects

Clinical Studies

Comparison with Other Neurotrophic Factors

CNTF in Alzheimer's Disease

Evidence for CNTF Involvement

Therapeutic Potential

CNTF in Multiple Sclerosis

Demyelination and Remyelination

CNTF and Neuroinflammation

Clinical Applications

CNTF and Neuroinflammation

CNTF in Other Neurodegenerative Conditions

Stroke and Ischemia

Huntington's Disease

Spinal Cord Injury

Cellular Sources and Targets

Cellular Sources of CNTF

Cellular Targets

Genetic Insights

CNTF Gene

CNTF Polymorphisms and Neurodegeneration

Epigenetic Regulation

Therapeutic Development

Recombinant CNTF

CNTF Mimetics

Gene Therapy Approaches

Cell-Based Delivery

Biomarker Potential

CNTF as a Biomarker

Therapeutic Monitoring

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

Research Directions

Unresolved Questions

Emerging Research Areas

Conclusion

See Also

External Links

Confidence Assessment

References

💬 Discussion